Mixed phase 2 trial results on psilocybin for Treatment-Resistant Depression
Mixed phase 2 trial results on psilocybin for Treatment-Resistant Depression
Overall positive news, as this trial provides evidence that a single 25 mg dose of psilocybin can significantly reduce depression severity scores.
During the trials an increase in suicidal ideation was also observed, showcasing that this form of therapy - while powerful and effective - is not a miracle cure that should be recommended without professional guidance.
0
comments